TY - JOUR T1 - The effect of serum activated ghrelin hormone on glycemic control in the diabetic patients with excessive body mass index AU - Kalyon, Semih AU - Fakı, Yilmaz PY - 2023 DA - May DO - 10.5472/marumj.1307861 JF - Marmara Medical Journal JO - Marmara Med J PB - Marmara University WT - DergiPark SN - 1019-1941 SP - 171 EP - 174 VL - 36 IS - 2 LA - en AB - Objective: In the literature, plasma ghrelin level was found to be lower in patients with obesity or diabetes in a few studies. However,there is no study comparing ghrelin level in non-diabetic and diabetic patients with overweight or obesity. We have two aims in thisstudy; first to show whether plasma ghrelin levels in type 2 diabetes mellitus patients with excessive body mass index (BMI) decreasethe level of a cumulative ghrelin which we expect in both diabetes-related and obesity-related conditions, secondly to study whetherthere is a correlation between ghrelin level and diabetes complications.Patients and Methods: Ethics committee decision and written informed consent from patients were received before the study. 57BMI≥25 type 2 diabetic patients treated and followed up in the diabetic outpatient clinic and 25 BMI≥25 subjects without diabetesmellitus (control group) were included in this case-control study. Pregnant women, patients with malignancy and under 18 years oldwere excluded. The results were evaluated by the SPSS statistical program.Results: The ghrelin and BMI values of the diabetic patients with excessive BMI and the non-diabetic patients with excessive BMI werenot statistically different. No statistical significant correlation between ghrelin and haemoglobin A1c (HbA1C), BMI, retinopathy,neuropathy, albuminuria, and macrovascular complications was found in the type 2 diabetic patients with overweight or obesity.Conclusion: The presence of diabetes in addition to patients with excessive BMI does not cause ghrelin levels to decrease more thanexpected. KW - Ghrelin KW - Diabetes Mellitus KW - Obesity KW - Overweight CR - [1] Poher A, Tschöp MH, Müller TD. Ghrelin regulation of glucose metabolism. Peptides 2018;100:236-42. doi: 10.1016/j. peptides.2017.12.015 CR - [2] Nakazato M, Murakami N, Date Y, et al. A role for Ghrelin in the central regulation of feeding. Nature 2001;409:194-8. doi: 10.1038/35051587 CR - [3] Hashizume T, Horiuchi M, Tate N, et al. Effects of Ghrelin on growth hormone secretion from cultured adenohypophysial cells in cattle. Endocr J 2003;50:289-95. doi: 10.1016/s0739- 7240(02)00240-0 CR - [4] Korbonits M, Goldstone AP, Gueorguiev M, Grossman AB. Grelin-a hormone with multiple functions. Front in Neuroend 2004;25:27-68. doi: 10.1016/j.yfrne.2004.03.002 CR - [5] Kojima M, Kangawa K. Grelin: structure and function. Physiol Rev 2005;85:495-522. doi : 10.1152/physrev.00012.2004 CR - [6] Aydin S, Ozkan Y, Caylak E, Aydin S. Grelin and its biochemical functions. Turkiye Klinikleri J Med Sci 2006;26:272-83. CR - [7] Inui A. Ghrelin an somatotrophic signal from the stomach. Nat Rev Nuerosci 2001;2:551 – 60. doi : 10.1038/35086018 CR - [8] Akamizu T, Kangawa K. Translational research on the clinical aplications of Ghrelin. Endocr J 2006;53:585-91. CR - [9] Toshinai K, Mondal MS, Nakazato M, et al. Upregulation of Ghrelin expression in the stomach upon fasting insulin induced hypoglycemia and leptin administration. Biochem. Biophys. Res Commun 2001;281:1220-5. doi 10.1006/ bbrc.2001.4518 CR - [10] Gaskin FS, Farr SA, Banks WA, Kumar VB, Morley JE. Ghrelin-induced feeding is dependent on nitric oxide. Peptides 2004;24:913 – 8. doi: 10.1016/s0196-9781(03)00160-8 CR - [11] Shintani M, Ogawa Y, Ebihara K, et al. Ghrelin, an endogenous growth hormone secretagogue is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 2001;50:227-32. doi: 10.2337/diabetes.50.2.227 CR - [12] Cummings DE, Weigle DS, Frayo RS, et al. Plasma Ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002;346:1623-30. doi: 10.1056/ NEJMoa012908 CR - [13] Tscho¨p M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating Ghrelin levels are decreased in human obesity. Diabetes 2001;50:707-9. doi: 10.2337/ diabetes.50.4.707 CR - [14] Shiiya T, Nakazato M, Mizuta M, Date Y, Mondal MS, Tanaka M. Plasma Ghrelin levels in lean and obese humans and the effect of glucose on Ghrelin secretion. J Clin Endocrinol Metab 2002;87:240-4. doi : 10.1210/jcem.87.1.8129 CR - [15] Verdeş G, DuŢă CC, Popescu R, MituleŢu M, Ursoniu S, Lazăr OF. Correlation between leptin and Ghrelin expression in adipose visceral tissue and clinical-biological features in malignant obesity. Rom J Morphol Embryol 2017;58:923-9. CR - [16] Katsuki A, Urakawa H, Gabazza EC, et al. Circulating levels of active Ghrelin is associated with abdominal adiposity, hyperinsulinemia and insulin resistance in patients with type 2 diabetes mellitus. Europ J Endocrinol 2004;151: 573-7. boi: 10.1530/eje.0.1510573 CR - [17] Flanagan DE, Evans ML, Monsod TP, et al. The influence of insulin on circulating Ghrelin. Am J Physiol Endocrinol Metab 2003;284:313-6. doi : 10.1152/ajpendo.00569.2001 CR - [18] Griffen SC, Oostema K, Stanhope KL et al. Administration of lispro insulin with meals improves glycemic control, increases circulating leptin, and suppresses Ghrelin compared with regular/NPH insulin in female patients with type 1 diabetes. J Clin Endocrinol Metab 2006;91:485-91. doi:10.1210/jc.2005- 1338 CR - [19] Ueno H, Shiiya T, Mizuta M, Mondal MS, Nakazato M. Plazma Ghrelin concentrations in different clinical stages of diabetic complications and glycemic control in Japanese diabetics. Endocrine J 2007;54:895-902. doi: https://doi.org/10.1507/ endocrj.K07-007 CR - [20] Kaçar AK, Saçan Ö, Öziçli N, Bolkent Ş, Yanardağ R, Bolkent S. The effects of Ghrelin on renal complications in newborn diabetic rats. Europ J Biol 2020;79;1-6. UR - https://doi.org/10.5472/marumj.1307861 L1 - https://dergipark.org.tr/en/download/article-file/3181235 ER -